– Ongoing BUENA Trial to Continue at Increased Daily Dose – SAINT LAURENT, Quebec, Jan. 15, 2020 (GLOBE NEWSWIRE) — IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that Health Canada has...
Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it has...
Clinical trial using devimistat in combination with FOLFIRINOX as first-line treatment has enrolled more than 250 patients ahead of scheduled timeline Cranbury, NJ, Jan. 14, 2020 (GLOBE NEWSWIRE) — Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a...
Three-arm, three-month study will compare Viveve’s cryogen-cooled monopolar radiofrequency (CMRF) treatment and cryogen-only sham to inert sham treatment ENGLEWOOD, CO / ACCESSWIRE / January 14, 2020 / Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology...
SEOUL, South Korea, Jan. 13, 2020 /PRNewswire/ — Genome & Company (KONEX: 314130) is pleased to announce that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to evaluate the safety,...
Health Authorities in the U.S. and U.K. Clear Path to Start of Clinical Trial, Patients Expected to be Dosed in Q1 2020 with Commercial Scale Material Potential 3rd Therapy to treat Phenylketonuria from Leader in PKU Therapies and 2nd Gene Therapy in Company’s...
Email
Text